21:44 , Oct 4, 2018 |  BC Innovations  |  Emerging Company Profile

Banking on exosomes

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from...
22:47 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest normalizing the ratio of tau four-repeat (4R) to tau 3R transcript levels could help treat tauopathies. In a mouse model of tauopathy, a lentiviral vector encoding a pre- trans -splicing...
13:38 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Selecta reports additional Phase II data for gout combo

Selecta Biosciences Inc. (NASDAQ:SELB) reported additional data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered...
22:53 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting LGALS1 could help treat pancreatic ductal adenocarcinoma (PDAC). In a human KRAS (K-Ras)-expressing mouse model of PDAC, systemic LGALS1 knockout increased survival compared with normal expression. In a...
18:22 , Mar 9, 2018 |  BC Week In Review  |  Company News

DNDi, partners aim to bring cheaper HCV combo to Latin America

The Drugs for Neglected Diseases initiative said it will partner with three pharmaceutical companies and a non-profit to sell a cheaper HCV regimen in Latin America. HCV patients pay at least $7,000 in Argentina, $12,000...
18:04 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

FDA approves Chemo's Chagas treatment

FDA granted accelerated approval to benznidazole from the Chemo Research S.L. unit of Chemo Group (Barcelona, Spain) to treat Chagas disease caused by Trypanosoma cruzi in children ages 2-12. FDA said the nitroimidazole antimicrobial is...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
16:55 , Jun 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Ischemia / reperfusion injury Cell culture and mouse studies suggest inhibition of TRPC3 , TRPC6 and TRPC7 could help treat ischemia/reperfusion injury. In a mouse model of the indication, cardiac tissue levels of TRPC3...
19:52 , Mar 15, 2017 |  BC Week In Review  |  Company News

Mast, University of Pittsburgh deal

Mast's Aires Pharmaceuticals Inc. subsidiary and the university partnered to conduct an open-label, dose-escalation, U.S. Phase I/II trial to evaluate the biotech's AIR001 to treat Pseudomonas aeruginosa airway infection in patients with cystic fibrosis (CF)....
07:00 , Apr 25, 2016 |  BC Week In Review  |  Company News

Protein Sciences, Sinergium, Mundo Sano deal

The partners formed a consortium to develop a Zika virus vaccine using Protein Sciences’ technology. Protein Sciences will receive an undisclosed upfront development and manufacturing payment from Sinergium. Sinergium will receive manufacturing and commercialization rights...